Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26310368 | 0.92 | NCF1 (0.43) | NCF1HRH3HRH4CTSBCTSS | |
| SCHEMBL26990573 | 0.88 | — | — | |
| SCHEMBL12561223 | 0.88 | — | — | |
| SCHEMBL22695352 | 0.80 | KDM1A (0.40) | NCF1HRH3ALDH1A1KDM1A | |
| SCHEMBL24609877 | 0.77 | HRH3 (0.41) | HRH3JAK2SYK | |
| SCHEMBL12561751 | 0.77 | NCF1 (0.46) | NCF1HRH3HRH4ACHEJAK2 | |
| SCHEMBL20842233 | 0.76 | — | — | |
| SCHEMBL20795823 | 0.76 | — | — | |
| SCHEMBL22691891 | 0.76 | MAOB (0.36) | JAK2JAK1TYK2JAK3ALDH1A1 | |
| SCHEMBL10503434 | 0.76 | NCF1 (0.50) | NCF1HRH3HRH4ACHEGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2022143628-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
| EP-3381920-B1 | CDK INHIBITORS | G1 THERAPEUTICS INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | ASANA BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2748166-B1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF | ASANA BIOSCIENCES LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| EP-2188253-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-26 | — | — | EP | disclosed |
| US-7557111-B2 | Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| WO-2009056707-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
| US-20090111835-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1787992-B1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20070254898-A1 | Thienopyrimidine and Thienopyridine Derivatives Substituted with Cyclic Amino Group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1787992-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | NCF1 3322/4885HRH3 911/4885HRH4 1387/4885 |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH4, CRHR1 | NCF1 517/4885HRH3 8/4885HRH4 2/4885 |
| US-20070254898-A1 | Thienopyrimidine and Thienopyridine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH3, HRH4 | NCF1 761/4885HRH3 2/4885HRH4 3/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | NCF1 1096/4885HRH3 3742/4885HRH4 3927/4885 |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | MKI67, DPYD, TYMP | NCF1 1078/4885HRH3 2015/4885HRH4 2224/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | NCF1 1078/4885HRH3 2015/4885HRH4 2224/4885 |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | NCF1 2682/4885HRH3 866/4885HRH4 697/4885 |
| US-20090111835-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH3, HRH4 | NCF1 645/4885HRH3 2/4885HRH4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.